Drugs Made In America Acquisition Corp. (DMAA) announced on September 8, 2026, that it has entered into an Amended and Restated Definitive Merger Agreement (A&R Merger Agreement) with Power Analytics Global Corp. (PAGC). The agreement amends and restates a series of prior agreements, including the Original Agreement dated April 29, 2026, and subsequent amendments.
The transaction is structured as a domestication of the Company to Delaware, followed by a merger of a wholly-owned subsidiary with and into PAGC. As part of the deal, PAGC is required to acquire APQC Inc. and the UltraSolar intellectual property prior to the closing of the merger. Completion of the APQC acquisition is a condition to the Company's obligation to close the merger.
The merger consideration is based on a fixed Closing Valuation of $2,850,000,000, determined on an asset basis. This replaces the previous valuation milestones contained in the original agreement. The consideration will be paid in the form of Domesticated DMAA Common Shares, calculated by dividing the Closing Valuation by the Reference Price. The Reference Price is defined as the greater of $10.75 or the per share redemption value of the Company's ordinary shares.
The transaction is subject to several conditions, including the approval of the Company’s shareholders and PAGC stockholders, the effectiveness of a Registration Statement, and the availability of at least $15,000,000 in Available Closing Cash. The Company’s obligation to close is further contingent upon the delivery of a Fairness Opinion and the absence of a Material Adverse Effect with respect to PAGC.
